Danuglipron Pfizer oral GLP-1 obesity T2D

Indicated For

obesity, T2D

About This Medication

# Pfizer Patient Assistance Program Guide: How to Get Danuglipron at Low or No Cost **Important Notice:** Danuglipron (PF-06882961) is an investigational oral GLP-1 receptor agonist developed by Pfizer for chronic weight management and type 2 diabetes. As of recent announcements, Pfizer has discontinued its clinical development due to safety concerns, including a case of potential drug-induced liver injury. It is not FDA-approved or commercially available. No specific patient assistance program exists for danuglipron. This guide covers Pfizer's general Patient Assistance Program (PAP), which may apply if the drug becomes available or for other Pfizer medications. Always consult your healthcare provider for current status. ## About Danuglipron Danuglipron was Pfizer's oral small-molecule GLP-1 receptor agonist, studied for obesity and type 2 diabetes (T2DM). Phase 2 trials showed significant weight reductions (up to 11.7% in twice-daily dosing), but high gastrointestinal side effects like nausea, vomiting, and diarrhea led to high discontinuation rates. Pfizer shifted to once-daily formulations, which met pharmacokinetic goals, but development halted after liver enzyme elevations and one asymptomatic liver injury case, resolved post-discontinuation.[1][2][6] **Key Facts:** - **Mechanism:** Mimics GLP-1 hormone to reduce appetite, slow gastric emptying, and improve blood sugar control. - **Status:** Development discontinued; not available via prescription.[1][7] - **Why Discontinued:** Safety review, regulator input, despite competitive efficacy potential.[1][6] If approved in the future, it could offer a pill alternative to injectables like semaglutide (Ozempic/Wegovy). ## Who Qualifies for Pfizer Patient Assistance Program? Pfizer's PAP provides free medications to uninsured or underinsured US residents meeting financial criteria. Eligibility typically requires: - US citizen or legal resident. - Household income at or below **400-500% of the Federal Poverty Level (FPL)** (varies by drug; exact danuglipron thresholds unavailable as drug is not launched). - No or limited prescription insurance. - Valid prescription from a US-licensed provider. Since danuglipron lacks a specific program, apply via Pfizer's general PAP if eligible in future.[5] ## Income Eligibility Breakdown Pfizer PAP income limits are generally up to 400-500% FPL, adjusted annually. Below is a sample table based on 2026 FPL estimates (confirm current guidelines at application). Exact danuglipron details: unavailable. | Household Size | 100% FPL | 400% FPL | 500% FPL | |----------------|----------|----------|----------| | 1 (Individual) | $15,060 | $60,240 | $75,300 | | 2 (Couple) | $20,440 | $81,760 | $102,200| | 3 | $25,820 | $103,280| $129,100| | 4 | $31,200 | $124,800| $156,000| *Notes:* Add ~$5,380 per additional person. Limits may be higher for some drugs. Medicare Part D enrollees often ineligible.[5] ## Insurance Requirements - **Uninsured or underinsured:** Primary option. - **Medicare:** Most Part D/Med Advantage patients ineligible; exceptions rare. - **Private insurance:** May qualify if high copays/deductibles and income criteria met. - **Medicaid:** Generally ineligible. Pfizer RxPathways helps navigate options.[5] ## Step-by-Step Application Process 1. **Confirm Eligibility:** Use Pfizer's online screener or call 1-844-989-7284 (RxPathways). 2. **Get Prescription:** From your doctor, specifying danuglipron (if available). 3. **Gather Documents:** Proof of income (tax returns, pay stubs), residency, prescription, insurance denial (if applicable). 4. **Apply Online or Mail:** Via pfizerpatientassistance.com or RxPathways.org. Download forms. 5. **Submit:** Electronically preferred; processing starts upon receipt. 6. **Follow Up:** Track status via portal or phone.[5] ## Timeline and Delivery - **Processing:** 2-4 weeks typically. - **Approval:** Medication shipped to doctor's office or home. - **Supply:** 1-12 months per approval; reapply as needed. Delays possible if docs incomplete.[5] ## Alternatives if Denied or Unavailable - **Other Pfizer PAPs:** For approved GLP-1s if any. - **Competitor Programs:** Novo Nordisk PAP (Wegovy/Ozempic), Eli Lilly (Zepbound/Mounjaro). - **General Aid:** NeedyMeds, RxAssist, Partnership for Prescription Assistance. - **Clinical Trials:** Check ClinicalTrials.gov for similar drugs (danuglipron trials closed). - **Lifestyle/Other Meds:** Doctor-guided diet, exercise, approved orals like metformin. ## Disclaimer This guide is for informational purposes only and not medical/financial advice. Danuglipron is not available; program details subject to change. Consult healthcare provider/pharmacist. Pfizer may update PAP rules. Data current as of 2026; verify at source. Not affiliated with Pfizer.

Program information last verified: March 30, 2026